Vivo Bio Tech Intrinsic Value
Vivo Bio Tech intrinsic value. Vivo Bio Tech (VIVOBIOT) median intrinsic value is ₹35.80 from 8 valuation models (range ₹13–₹43), vs current price ₹14.32 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. Browse Vivo Bio Tech financial data for revenue, profit, balance sheet and cash flow data.
VIVOBIOT Valuation Methods Summary — DCF, Graham Number & P/E
Vivo Bio Tech intrinsic value across 8 models vs current price ₹14.32 — upside/downside and value range per method. For current market price and key ratios, visit Vivo Bio Tech share price chart.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹42.96 | ₹34.37 - ₹51.55 | +200.0% | EPS: ₹2.00, Sector P/E: 22x |
| Book Value Method | asset | ₹35.80 | ₹32.22 - ₹39.38 | +150.0% | Book Value/Share: ₹42.27, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹28.64 | ₹25.78 - ₹31.50 | +100.0% | Revenue/Share: ₹34.55, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹28.64 | ₹25.78 - ₹31.50 | +100.0% | EBITDA: ₹32.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹35.80 | ₹28.64 - ₹42.96 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹12.80 | ₹11.52 - ₹14.08 | -10.6% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹30.90 | ₹27.81 - ₹33.99 | +115.8% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹42.96 | ₹38.66 - ₹47.26 | +200.0% | EPS: ₹2.00, BVPS: ₹42.27 |
VIVOBIOT Intrinsic Value vs Market Price — All Valuation Models
Vivo Bio Tech fair value range ₹13–₹43 vs current market price ₹14.32 across 8 valuation models. Analyse Vivo Bio Tech shareholding analysis to track promoter, FII and institutional holdings.
VIVOBIOT Intrinsic Value Analysis — Undervalued or Overvalued?
Vivo Bio Tech median intrinsic value ₹35.80, current price ₹14.32 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of VIVOBIOT?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Vivo Bio Tech (VIVOBIOT) is ₹35.80 (median value). With the current market price of ₹14.32, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹12.80 to ₹42.96, indicating ₹12.80 - ₹42.96.
Is VIVOBIOT undervalued or overvalued?
Based on our multi-method analysis, Vivo Bio Tech (VIVOBIOT) appears to be trading below calculated value by approximately 150.0%.
VIVOBIOT Financial Health — Key Ratios vs Industry Benchmarks
Vivo Bio Tech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 4.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 35.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.43x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
VIVOBIOT Cash Flow Quality — Operating & Free Cash Flow
Vivo Bio Tech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹35 Cr | ₹6 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹12 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹16 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹15 Cr | ₹13 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹17 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |